Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy

NCT07063212 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07063212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07063212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 2, 2025
Completion date
January 2, 2028
Enrollment
40 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hpv positive oropharyngeal squamous cell carcinoma, hypopharynx cancer, hypopharynx squamous cell carcinoma, larynx cancer, larynx squamous cell carcinoma, nasal cavity cancer, oral cavity cancer, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, sinus cancer, squamous cell carcinoma of head and neck